Chromosome 12p Amplification in Triple-Negative/ BRCA1- Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

Taxanes are the mainstay of treatment in triple-negative breast cancer (TNBC), with and acquired resistance limiting patient's survival. To investigate the genetic basis of docetaxel resistance in TNBC, exome sequencing was performed on matched TNBC patient-derived xenografts (PDX) sensitive to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2019-08, Vol.79 (16), p.4258-4270
Hauptverfasser: Gómez-Miragaya, Jorge, Díaz-Navarro, Ander, Tonda, Raul, Beltran, Sergi, Palomero, Luis, Palafox, Marta, Dobrolecki, Lacey E, Huang, Chen, Vasaikar, Suhas, Zhang, Bing, Wulf, Gerburg M, Collado-Sole, Alejandro, Trinidad, Eva M, Muñoz, Purificación, Paré, Laia, Prat, Aleix, Bruna, Alejandra, Caldas, Carlos, Arribas, Joaquín, Soler-Monso, María Teresa, Petit, Anna, Balmaña, Judith, Cruz, Cristina, Serra, Violeta, Pujana, Miguel Angel, Lewis, Michael T, Puente, Xose S, González-Suárez, Eva
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4270
container_issue 16
container_start_page 4258
container_title Cancer research (Chicago, Ill.)
container_volume 79
creator Gómez-Miragaya, Jorge
Díaz-Navarro, Ander
Tonda, Raul
Beltran, Sergi
Palomero, Luis
Palafox, Marta
Dobrolecki, Lacey E
Huang, Chen
Vasaikar, Suhas
Zhang, Bing
Wulf, Gerburg M
Collado-Sole, Alejandro
Trinidad, Eva M
Muñoz, Purificación
Paré, Laia
Prat, Aleix
Bruna, Alejandra
Caldas, Carlos
Arribas, Joaquín
Soler-Monso, María Teresa
Petit, Anna
Balmaña, Judith
Cruz, Cristina
Serra, Violeta
Pujana, Miguel Angel
Lewis, Michael T
Puente, Xose S
González-Suárez, Eva
description Taxanes are the mainstay of treatment in triple-negative breast cancer (TNBC), with and acquired resistance limiting patient's survival. To investigate the genetic basis of docetaxel resistance in TNBC, exome sequencing was performed on matched TNBC patient-derived xenografts (PDX) sensitive to docetaxel and their counterparts that developed resistance upon continuous drug exposure. Most mutations, small insertions/deletions, and copy number alterations detected in the initial TNBC human metastatic samples were maintained after serial passages in mice and emergence of resistance. We identified a chromosomal amplification of chr12p in a human -mutated metastatic sample and the derived chemoresistant PDX, but not in the matched docetaxel-sensitive PDX tumor. Chr12p amplification was validated in a second pair of docetaxel-sensitive/resistant -mutated PDXs and after short-term docetaxel treatment in several TNBC/ -mutated PDXs and cell lines, as well as during metastatic recurrence in a patient with -mutated breast cancer who had progressed on docetaxel treatment. Analysis of clinical data indicates an association between chr12p amplification and patients with TNBC/basal-like breast cancer, a mutational signature, and poor survival after chemotherapy. Detection of chr12p amplification in a cohort of TNBC PDX models was associated with an improved response to carboplatin. Our findings reveal tumor clonal dynamics during chemotherapy treatments and suggest that a preexisting population harboring chr12p amplification is associated with the emergence of docetaxel resistance and carboplatin responsiveness in TNBC/ -mutated tumors. SIGNIFICANCE: Chr12p copy number gains indicate rapid emergence of resistance to docetaxel and increased sensitivity to carboplatin, therefore sequential docetaxel/carboplatin treatment could improve survival in TNBC/ patients. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/16/4258/F1.large.jpg.
doi_str_mv 10.1158/0008-5472.CAN-18-3835
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7616973</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2243502735</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-b429201116e777842b5448e039ea202ecb3b36254df6c25d2aa48c818aba864c3</originalsourceid><addsrcrecordid>eNpVkV1P1TAYxxsjkQP6ETS99GbQ163nxmQMEBLEBPG66bpn59Rs62x7UD6LX9YuwIleNe3_rckPofeUnFAq1SkhRBVSVOykqW8LqgquuHyFVlRyVVRCyNdotfccoqMYf-SrpES-QYecMspFKVfoT7MNfvTRj4Apm3E9zoPrnTXJ-Qm7Cd8HNw9Q3MImPz3AKT67a2pa4C-7ZBJ0-CyAiQk3ZrIQcB2jty4LEf9yaYsvRggbyBL2PT73FpL5DQO-g-hiWiLYTF0Oh9bPQx6Y8DeYostLLj2-RQe9GSK8ez6P0ffLi_vmqrj5-vm6qW8KK0qeilawNSOU0hKqqlKCtVIIBYSvwTDCwLa85SWToutLy2THjBHKKqpMa1QpLD9Gn5565107QmdhSsEMeg5uNOFRe-P0_8rktnrjH3RV0nJd8Vzw8bkg-J87iEmPLloYBjOB30XNmOCSsIrLbJVPVht8jAH6_QwlegGrF2h6gaYzWE2VXsDm3Id__7hPvZDkfwF6B6Er</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2243502735</pqid></control><display><type>article</type><title>Chromosome 12p Amplification in Triple-Negative/ BRCA1- Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Gómez-Miragaya, Jorge ; Díaz-Navarro, Ander ; Tonda, Raul ; Beltran, Sergi ; Palomero, Luis ; Palafox, Marta ; Dobrolecki, Lacey E ; Huang, Chen ; Vasaikar, Suhas ; Zhang, Bing ; Wulf, Gerburg M ; Collado-Sole, Alejandro ; Trinidad, Eva M ; Muñoz, Purificación ; Paré, Laia ; Prat, Aleix ; Bruna, Alejandra ; Caldas, Carlos ; Arribas, Joaquín ; Soler-Monso, María Teresa ; Petit, Anna ; Balmaña, Judith ; Cruz, Cristina ; Serra, Violeta ; Pujana, Miguel Angel ; Lewis, Michael T ; Puente, Xose S ; González-Suárez, Eva</creator><creatorcontrib>Gómez-Miragaya, Jorge ; Díaz-Navarro, Ander ; Tonda, Raul ; Beltran, Sergi ; Palomero, Luis ; Palafox, Marta ; Dobrolecki, Lacey E ; Huang, Chen ; Vasaikar, Suhas ; Zhang, Bing ; Wulf, Gerburg M ; Collado-Sole, Alejandro ; Trinidad, Eva M ; Muñoz, Purificación ; Paré, Laia ; Prat, Aleix ; Bruna, Alejandra ; Caldas, Carlos ; Arribas, Joaquín ; Soler-Monso, María Teresa ; Petit, Anna ; Balmaña, Judith ; Cruz, Cristina ; Serra, Violeta ; Pujana, Miguel Angel ; Lewis, Michael T ; Puente, Xose S ; González-Suárez, Eva</creatorcontrib><description>Taxanes are the mainstay of treatment in triple-negative breast cancer (TNBC), with and acquired resistance limiting patient's survival. To investigate the genetic basis of docetaxel resistance in TNBC, exome sequencing was performed on matched TNBC patient-derived xenografts (PDX) sensitive to docetaxel and their counterparts that developed resistance upon continuous drug exposure. Most mutations, small insertions/deletions, and copy number alterations detected in the initial TNBC human metastatic samples were maintained after serial passages in mice and emergence of resistance. We identified a chromosomal amplification of chr12p in a human -mutated metastatic sample and the derived chemoresistant PDX, but not in the matched docetaxel-sensitive PDX tumor. Chr12p amplification was validated in a second pair of docetaxel-sensitive/resistant -mutated PDXs and after short-term docetaxel treatment in several TNBC/ -mutated PDXs and cell lines, as well as during metastatic recurrence in a patient with -mutated breast cancer who had progressed on docetaxel treatment. Analysis of clinical data indicates an association between chr12p amplification and patients with TNBC/basal-like breast cancer, a mutational signature, and poor survival after chemotherapy. Detection of chr12p amplification in a cohort of TNBC PDX models was associated with an improved response to carboplatin. Our findings reveal tumor clonal dynamics during chemotherapy treatments and suggest that a preexisting population harboring chr12p amplification is associated with the emergence of docetaxel resistance and carboplatin responsiveness in TNBC/ -mutated tumors. SIGNIFICANCE: Chr12p copy number gains indicate rapid emergence of resistance to docetaxel and increased sensitivity to carboplatin, therefore sequential docetaxel/carboplatin treatment could improve survival in TNBC/ patients. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/16/4258/F1.large.jpg.</description><identifier>ISSN: 0008-5472</identifier><identifier>ISSN: 1538-7445</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/0008-5472.CAN-18-3835</identifier><identifier>PMID: 31213465</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; BRCA1 Protein - genetics ; Carboplatin - pharmacology ; Cell Line, Tumor ; Chromosomes, Human, Pair 12 ; Docetaxel - pharmacology ; Drug Resistance, Neoplasm - genetics ; Exome ; Female ; Humans ; Mice ; Mutation ; Treatment Outcome ; Triple Negative Breast Neoplasms - drug therapy ; Triple Negative Breast Neoplasms - genetics ; Triple Negative Breast Neoplasms - mortality ; Xenograft Model Antitumor Assays</subject><ispartof>Cancer research (Chicago, Ill.), 2019-08, Vol.79 (16), p.4258-4270</ispartof><rights>2019 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-b429201116e777842b5448e039ea202ecb3b36254df6c25d2aa48c818aba864c3</citedby><cites>FETCH-LOGICAL-c463t-b429201116e777842b5448e039ea202ecb3b36254df6c25d2aa48c818aba864c3</cites><orcidid>0000-0001-6620-1065 ; 0000-0001-6808-4800 ; 0000-0001-6090-5205 ; 0000-0002-3751-2099 ; 0000-0002-6474-7504 ; 0000-0002-0504-0664 ; 0000-0003-1801-4681 ; 0000-0001-8676-2425 ; 0000-0003-3222-4044 ; 0000-0001-9525-1483 ; 0000-0001-7893-2404</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31213465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gómez-Miragaya, Jorge</creatorcontrib><creatorcontrib>Díaz-Navarro, Ander</creatorcontrib><creatorcontrib>Tonda, Raul</creatorcontrib><creatorcontrib>Beltran, Sergi</creatorcontrib><creatorcontrib>Palomero, Luis</creatorcontrib><creatorcontrib>Palafox, Marta</creatorcontrib><creatorcontrib>Dobrolecki, Lacey E</creatorcontrib><creatorcontrib>Huang, Chen</creatorcontrib><creatorcontrib>Vasaikar, Suhas</creatorcontrib><creatorcontrib>Zhang, Bing</creatorcontrib><creatorcontrib>Wulf, Gerburg M</creatorcontrib><creatorcontrib>Collado-Sole, Alejandro</creatorcontrib><creatorcontrib>Trinidad, Eva M</creatorcontrib><creatorcontrib>Muñoz, Purificación</creatorcontrib><creatorcontrib>Paré, Laia</creatorcontrib><creatorcontrib>Prat, Aleix</creatorcontrib><creatorcontrib>Bruna, Alejandra</creatorcontrib><creatorcontrib>Caldas, Carlos</creatorcontrib><creatorcontrib>Arribas, Joaquín</creatorcontrib><creatorcontrib>Soler-Monso, María Teresa</creatorcontrib><creatorcontrib>Petit, Anna</creatorcontrib><creatorcontrib>Balmaña, Judith</creatorcontrib><creatorcontrib>Cruz, Cristina</creatorcontrib><creatorcontrib>Serra, Violeta</creatorcontrib><creatorcontrib>Pujana, Miguel Angel</creatorcontrib><creatorcontrib>Lewis, Michael T</creatorcontrib><creatorcontrib>Puente, Xose S</creatorcontrib><creatorcontrib>González-Suárez, Eva</creatorcontrib><title>Chromosome 12p Amplification in Triple-Negative/ BRCA1- Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Taxanes are the mainstay of treatment in triple-negative breast cancer (TNBC), with and acquired resistance limiting patient's survival. To investigate the genetic basis of docetaxel resistance in TNBC, exome sequencing was performed on matched TNBC patient-derived xenografts (PDX) sensitive to docetaxel and their counterparts that developed resistance upon continuous drug exposure. Most mutations, small insertions/deletions, and copy number alterations detected in the initial TNBC human metastatic samples were maintained after serial passages in mice and emergence of resistance. We identified a chromosomal amplification of chr12p in a human -mutated metastatic sample and the derived chemoresistant PDX, but not in the matched docetaxel-sensitive PDX tumor. Chr12p amplification was validated in a second pair of docetaxel-sensitive/resistant -mutated PDXs and after short-term docetaxel treatment in several TNBC/ -mutated PDXs and cell lines, as well as during metastatic recurrence in a patient with -mutated breast cancer who had progressed on docetaxel treatment. Analysis of clinical data indicates an association between chr12p amplification and patients with TNBC/basal-like breast cancer, a mutational signature, and poor survival after chemotherapy. Detection of chr12p amplification in a cohort of TNBC PDX models was associated with an improved response to carboplatin. Our findings reveal tumor clonal dynamics during chemotherapy treatments and suggest that a preexisting population harboring chr12p amplification is associated with the emergence of docetaxel resistance and carboplatin responsiveness in TNBC/ -mutated tumors. SIGNIFICANCE: Chr12p copy number gains indicate rapid emergence of resistance to docetaxel and increased sensitivity to carboplatin, therefore sequential docetaxel/carboplatin treatment could improve survival in TNBC/ patients. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/16/4258/F1.large.jpg.</description><subject>Animals</subject><subject>BRCA1 Protein - genetics</subject><subject>Carboplatin - pharmacology</subject><subject>Cell Line, Tumor</subject><subject>Chromosomes, Human, Pair 12</subject><subject>Docetaxel - pharmacology</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Exome</subject><subject>Female</subject><subject>Humans</subject><subject>Mice</subject><subject>Mutation</subject><subject>Treatment Outcome</subject><subject>Triple Negative Breast Neoplasms - drug therapy</subject><subject>Triple Negative Breast Neoplasms - genetics</subject><subject>Triple Negative Breast Neoplasms - mortality</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0008-5472</issn><issn>1538-7445</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkV1P1TAYxxsjkQP6ETS99GbQ163nxmQMEBLEBPG66bpn59Rs62x7UD6LX9YuwIleNe3_rckPofeUnFAq1SkhRBVSVOykqW8LqgquuHyFVlRyVVRCyNdotfccoqMYf-SrpES-QYecMspFKVfoT7MNfvTRj4Apm3E9zoPrnTXJ-Qm7Cd8HNw9Q3MImPz3AKT67a2pa4C-7ZBJ0-CyAiQk3ZrIQcB2jty4LEf9yaYsvRggbyBL2PT73FpL5DQO-g-hiWiLYTF0Oh9bPQx6Y8DeYostLLj2-RQe9GSK8ez6P0ffLi_vmqrj5-vm6qW8KK0qeilawNSOU0hKqqlKCtVIIBYSvwTDCwLa85SWToutLy2THjBHKKqpMa1QpLD9Gn5565107QmdhSsEMeg5uNOFRe-P0_8rktnrjH3RV0nJd8Vzw8bkg-J87iEmPLloYBjOB30XNmOCSsIrLbJVPVht8jAH6_QwlegGrF2h6gaYzWE2VXsDm3Id__7hPvZDkfwF6B6Er</recordid><startdate>20190815</startdate><enddate>20190815</enddate><creator>Gómez-Miragaya, Jorge</creator><creator>Díaz-Navarro, Ander</creator><creator>Tonda, Raul</creator><creator>Beltran, Sergi</creator><creator>Palomero, Luis</creator><creator>Palafox, Marta</creator><creator>Dobrolecki, Lacey E</creator><creator>Huang, Chen</creator><creator>Vasaikar, Suhas</creator><creator>Zhang, Bing</creator><creator>Wulf, Gerburg M</creator><creator>Collado-Sole, Alejandro</creator><creator>Trinidad, Eva M</creator><creator>Muñoz, Purificación</creator><creator>Paré, Laia</creator><creator>Prat, Aleix</creator><creator>Bruna, Alejandra</creator><creator>Caldas, Carlos</creator><creator>Arribas, Joaquín</creator><creator>Soler-Monso, María Teresa</creator><creator>Petit, Anna</creator><creator>Balmaña, Judith</creator><creator>Cruz, Cristina</creator><creator>Serra, Violeta</creator><creator>Pujana, Miguel Angel</creator><creator>Lewis, Michael T</creator><creator>Puente, Xose S</creator><creator>González-Suárez, Eva</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6620-1065</orcidid><orcidid>https://orcid.org/0000-0001-6808-4800</orcidid><orcidid>https://orcid.org/0000-0001-6090-5205</orcidid><orcidid>https://orcid.org/0000-0002-3751-2099</orcidid><orcidid>https://orcid.org/0000-0002-6474-7504</orcidid><orcidid>https://orcid.org/0000-0002-0504-0664</orcidid><orcidid>https://orcid.org/0000-0003-1801-4681</orcidid><orcidid>https://orcid.org/0000-0001-8676-2425</orcidid><orcidid>https://orcid.org/0000-0003-3222-4044</orcidid><orcidid>https://orcid.org/0000-0001-9525-1483</orcidid><orcidid>https://orcid.org/0000-0001-7893-2404</orcidid></search><sort><creationdate>20190815</creationdate><title>Chromosome 12p Amplification in Triple-Negative/ BRCA1- Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity</title><author>Gómez-Miragaya, Jorge ; Díaz-Navarro, Ander ; Tonda, Raul ; Beltran, Sergi ; Palomero, Luis ; Palafox, Marta ; Dobrolecki, Lacey E ; Huang, Chen ; Vasaikar, Suhas ; Zhang, Bing ; Wulf, Gerburg M ; Collado-Sole, Alejandro ; Trinidad, Eva M ; Muñoz, Purificación ; Paré, Laia ; Prat, Aleix ; Bruna, Alejandra ; Caldas, Carlos ; Arribas, Joaquín ; Soler-Monso, María Teresa ; Petit, Anna ; Balmaña, Judith ; Cruz, Cristina ; Serra, Violeta ; Pujana, Miguel Angel ; Lewis, Michael T ; Puente, Xose S ; González-Suárez, Eva</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-b429201116e777842b5448e039ea202ecb3b36254df6c25d2aa48c818aba864c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>BRCA1 Protein - genetics</topic><topic>Carboplatin - pharmacology</topic><topic>Cell Line, Tumor</topic><topic>Chromosomes, Human, Pair 12</topic><topic>Docetaxel - pharmacology</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Exome</topic><topic>Female</topic><topic>Humans</topic><topic>Mice</topic><topic>Mutation</topic><topic>Treatment Outcome</topic><topic>Triple Negative Breast Neoplasms - drug therapy</topic><topic>Triple Negative Breast Neoplasms - genetics</topic><topic>Triple Negative Breast Neoplasms - mortality</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gómez-Miragaya, Jorge</creatorcontrib><creatorcontrib>Díaz-Navarro, Ander</creatorcontrib><creatorcontrib>Tonda, Raul</creatorcontrib><creatorcontrib>Beltran, Sergi</creatorcontrib><creatorcontrib>Palomero, Luis</creatorcontrib><creatorcontrib>Palafox, Marta</creatorcontrib><creatorcontrib>Dobrolecki, Lacey E</creatorcontrib><creatorcontrib>Huang, Chen</creatorcontrib><creatorcontrib>Vasaikar, Suhas</creatorcontrib><creatorcontrib>Zhang, Bing</creatorcontrib><creatorcontrib>Wulf, Gerburg M</creatorcontrib><creatorcontrib>Collado-Sole, Alejandro</creatorcontrib><creatorcontrib>Trinidad, Eva M</creatorcontrib><creatorcontrib>Muñoz, Purificación</creatorcontrib><creatorcontrib>Paré, Laia</creatorcontrib><creatorcontrib>Prat, Aleix</creatorcontrib><creatorcontrib>Bruna, Alejandra</creatorcontrib><creatorcontrib>Caldas, Carlos</creatorcontrib><creatorcontrib>Arribas, Joaquín</creatorcontrib><creatorcontrib>Soler-Monso, María Teresa</creatorcontrib><creatorcontrib>Petit, Anna</creatorcontrib><creatorcontrib>Balmaña, Judith</creatorcontrib><creatorcontrib>Cruz, Cristina</creatorcontrib><creatorcontrib>Serra, Violeta</creatorcontrib><creatorcontrib>Pujana, Miguel Angel</creatorcontrib><creatorcontrib>Lewis, Michael T</creatorcontrib><creatorcontrib>Puente, Xose S</creatorcontrib><creatorcontrib>González-Suárez, Eva</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gómez-Miragaya, Jorge</au><au>Díaz-Navarro, Ander</au><au>Tonda, Raul</au><au>Beltran, Sergi</au><au>Palomero, Luis</au><au>Palafox, Marta</au><au>Dobrolecki, Lacey E</au><au>Huang, Chen</au><au>Vasaikar, Suhas</au><au>Zhang, Bing</au><au>Wulf, Gerburg M</au><au>Collado-Sole, Alejandro</au><au>Trinidad, Eva M</au><au>Muñoz, Purificación</au><au>Paré, Laia</au><au>Prat, Aleix</au><au>Bruna, Alejandra</au><au>Caldas, Carlos</au><au>Arribas, Joaquín</au><au>Soler-Monso, María Teresa</au><au>Petit, Anna</au><au>Balmaña, Judith</au><au>Cruz, Cristina</au><au>Serra, Violeta</au><au>Pujana, Miguel Angel</au><au>Lewis, Michael T</au><au>Puente, Xose S</au><au>González-Suárez, Eva</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chromosome 12p Amplification in Triple-Negative/ BRCA1- Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>2019-08-15</date><risdate>2019</risdate><volume>79</volume><issue>16</issue><spage>4258</spage><epage>4270</epage><pages>4258-4270</pages><issn>0008-5472</issn><issn>1538-7445</issn><eissn>1538-7445</eissn><abstract>Taxanes are the mainstay of treatment in triple-negative breast cancer (TNBC), with and acquired resistance limiting patient's survival. To investigate the genetic basis of docetaxel resistance in TNBC, exome sequencing was performed on matched TNBC patient-derived xenografts (PDX) sensitive to docetaxel and their counterparts that developed resistance upon continuous drug exposure. Most mutations, small insertions/deletions, and copy number alterations detected in the initial TNBC human metastatic samples were maintained after serial passages in mice and emergence of resistance. We identified a chromosomal amplification of chr12p in a human -mutated metastatic sample and the derived chemoresistant PDX, but not in the matched docetaxel-sensitive PDX tumor. Chr12p amplification was validated in a second pair of docetaxel-sensitive/resistant -mutated PDXs and after short-term docetaxel treatment in several TNBC/ -mutated PDXs and cell lines, as well as during metastatic recurrence in a patient with -mutated breast cancer who had progressed on docetaxel treatment. Analysis of clinical data indicates an association between chr12p amplification and patients with TNBC/basal-like breast cancer, a mutational signature, and poor survival after chemotherapy. Detection of chr12p amplification in a cohort of TNBC PDX models was associated with an improved response to carboplatin. Our findings reveal tumor clonal dynamics during chemotherapy treatments and suggest that a preexisting population harboring chr12p amplification is associated with the emergence of docetaxel resistance and carboplatin responsiveness in TNBC/ -mutated tumors. SIGNIFICANCE: Chr12p copy number gains indicate rapid emergence of resistance to docetaxel and increased sensitivity to carboplatin, therefore sequential docetaxel/carboplatin treatment could improve survival in TNBC/ patients. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/16/4258/F1.large.jpg.</abstract><cop>United States</cop><pmid>31213465</pmid><doi>10.1158/0008-5472.CAN-18-3835</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-6620-1065</orcidid><orcidid>https://orcid.org/0000-0001-6808-4800</orcidid><orcidid>https://orcid.org/0000-0001-6090-5205</orcidid><orcidid>https://orcid.org/0000-0002-3751-2099</orcidid><orcidid>https://orcid.org/0000-0002-6474-7504</orcidid><orcidid>https://orcid.org/0000-0002-0504-0664</orcidid><orcidid>https://orcid.org/0000-0003-1801-4681</orcidid><orcidid>https://orcid.org/0000-0001-8676-2425</orcidid><orcidid>https://orcid.org/0000-0003-3222-4044</orcidid><orcidid>https://orcid.org/0000-0001-9525-1483</orcidid><orcidid>https://orcid.org/0000-0001-7893-2404</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 2019-08, Vol.79 (16), p.4258-4270
issn 0008-5472
1538-7445
1538-7445
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7616973
source MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Animals
BRCA1 Protein - genetics
Carboplatin - pharmacology
Cell Line, Tumor
Chromosomes, Human, Pair 12
Docetaxel - pharmacology
Drug Resistance, Neoplasm - genetics
Exome
Female
Humans
Mice
Mutation
Treatment Outcome
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - genetics
Triple Negative Breast Neoplasms - mortality
Xenograft Model Antitumor Assays
title Chromosome 12p Amplification in Triple-Negative/ BRCA1- Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A42%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chromosome%2012p%20Amplification%20in%20Triple-Negative/%20BRCA1-%20Mutated%20Breast%20Cancer%20Associates%20with%20Emergence%20of%20Docetaxel%20Resistance%20and%20Carboplatin%20Sensitivity&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=G%C3%B3mez-Miragaya,%20Jorge&rft.date=2019-08-15&rft.volume=79&rft.issue=16&rft.spage=4258&rft.epage=4270&rft.pages=4258-4270&rft.issn=0008-5472&rft.eissn=1538-7445&rft_id=info:doi/10.1158/0008-5472.CAN-18-3835&rft_dat=%3Cproquest_pubme%3E2243502735%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2243502735&rft_id=info:pmid/31213465&rfr_iscdi=true